A Phase 2 interventional study of Bradanicline and Placebo in Chronic Cough, sponsored by Attenua, Inc.. Completed at 17 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-06-20.
Sponsored by Attenua, Inc. · Phase 2, Interventional, and Treatment
This is a randomized, double-blind, placebo-controlled, crossover, dose escalation study of bradanicline in subjects with chronic cough
This study will have two 21-day treatment periods separated by a 14-day washout period. There will be a 14-day follow-up period.
346 studies on the registry are indexed under Cough; 71 are open to participants now.
This study's enrollment of 46 is below the median of 70 across 263 interventional studies indexed under Cough.
Browse Cough studies →This is the only study on the registry with Attenua, Inc. as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Randomized crossover design of 3 different doses of bradanicline (film-coated tablets) to be administered orally QD
Drug: Bradanicline · Drug: Placebo
Randomized crossover design of matching placebo tablets to be administered orally QD
Drug: Bradanicline · Drug: Placebo
Three different doses over the course of the study
Matching placebo for Bradanicline
Awake coughs per hour at Days 7, 14, 21, 43, 50, 57
Assessment of awake coughs per hour (average hourly cough frequency while the participant is awake based on sound recordings), to be evaluated using a digital recording device
Time frame: Change from Baseline at Days 7, 14, 21, 43, 50, 57
24-hour coughs per hour at Days 7, 14, 21, 43, 50, 57
Assessment of 24-hour coughs per hour (average hourly cough frequency based on 24-hour sound recordings), to be evaluated using a digital recording device
Time frame: Change from Baseline at Days 7, 14, 21, 43, 50, 57
Percentage of participants who have at least one adverse event (AE) during the treatment periods, washout, and follow-up
Assessment of participants who have at least one AE during treatment period 1 (21 days), during washout (14 days), during treatment period 2 (21 days), and follow-up (14 days)
Time frame: up to 57 days
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.